



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## Miguel Sieler, former Chairman and C.E.O Bayer France, named C.E.O of Neovacs

**Paris, October 18 2013 – NEOVACS (Alternext Paris : ALNEV)**, a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that Miguel Sieler, former Chairman and Chief Executive Officer of Bayer France has been named Chief Executive Officer of Neovacs, replacing Guy-Charles Fanneau De La Horie.

*“Miguel Sieler will build on the work of Guy-Charles Fanneau De La Horie to make Neovacs a leading company in the field of therapeutic vaccines and increase the Company’s value” commented Jean-Jacques Bertrand, Chairman of Neovacs. He added: “We thank Guy-Charles who has built with success a strong technologic platform and has led into phase II very promising products targeting significant markets”.*

*« Neovacs develops breakthrough treatments, Kinoids, which activate patient’s immune system in order to neutralise the deregulation involved in the development of his/her disease. This innovative approach demonstrates Neovacs’ ambition to make Kinoids the next generation treatment for autoimmune and inflammatory diseases, and more specifically Rheumatoid Arthritis, Crohn’s Disease and lupus. My goal is to bring these products to world markets and build value-creating partnerships for investors » stated Miguel Sieler, CEO of Neovacs.*

Miguel Sieler will pursue the development of Neovacs and put a particular focus on the value of its pipeline. Neovacs is currently concentrating its R&D efforts on two immunotherapies in three severe indications : TNF-Kinoid in RA and Crohn’s Disease and IFN $\alpha$ -Kinoid in Lupus.

Miguel Sieler joined Bayer AG in 1975 for an international career which started at the group headquarters in Germany. He served in various senior management positions in Brussels and Sao Paulo before becoming President of Bayer in Korea, followed by 4 years as C.E.O of Bayer Pharma France. In 1998, Miguel Sieler became Chairman and CEO of the Bayer Group in France until his retirement in 2008. Miguel Sieler is also member of the Board of Nexity S.A. and Chairman of WittyCell, a French biotechnology company dedicated to the development of innovative vaccine adjuvants. Mr. Sieler holds a Master in Law degree from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France.

### **About Neovacs**

Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that run until at least 2026) Neovacs is

focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFN $\alpha$ -Kinoid is being developed for the indication of lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

**For more information on Neovacs, visit [www.neovacs.fr](http://www.neovacs.fr)**

**Contacts**

**Press – ALIZE RP**

Caroline Carmagnol  
+33 (0)1 42 68 86 43  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

**NEOVACS**

Nathalie Trépo  
+33 (0)1 53 10 93 00  
[ntrepo@neovacs.com](mailto:ntrepo@neovacs.com)

**Investors - NewCap**

Valentine Brouchet/Pierre Laurent  
+ 33 (0) 1 44 71 94 93  
[avuillermet@newcap.fr](mailto:avuillermet@newcap.fr)